Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2024Journal of Clinical Oncology

Treatment (Tx) inequities in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) harboring actionable driver oncogenes (ADO) in the first-line (1L) setting.

View Full Paper
Ask AI
Bookmark
Share

Authors

GVGregory A. VidalWest Cancer CenterTSThomas StrickerUniversity of GenevaEMEsprit MaKaiser Permanente South San Francisco Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Vidal et al. (2024) studied this question.

synapsesocial.com/papers/68e67f58b6db64358760839ehttps://doi.org/10.1200/jco.2024.42.16_suppl.e13673
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of guideline-recommended care in first-line treatment for advanced/metastatic non-small cell lung cancer patients who underwent next-generation sequencing testing: results from a real-world study2026
  2. 2A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.2024
  3. 3Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US).2024
  4. 4Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer2026
  5. 5Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices2026